Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Anika Therapeutics (ANIK) over the last 14 years, with Q3 2025 value amounting to $750000.0.

  • Anika Therapeutics' Other Accumulated Expenses rose 9841.27% to $750000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $750000.0, marking a year-over-year increase of 9841.27%. This contributed to the annual value of $765000.0 for FY2024, which is 12633.14% up from last year.
  • Latest data reveals that Anika Therapeutics reported Other Accumulated Expenses of $750000.0 as of Q3 2025, which was up 9841.27% from $641000.0 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Other Accumulated Expenses high stood at $17.3 million for Q3 2021, and its period low was $338000.0 during Q4 2023.
  • Its 5-year average for Other Accumulated Expenses is $2.4 million, with a median of $641000.0 in 2025.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 158176.53% in 2021, then tumbled by 9713.94% in 2022.
  • Over the past 5 years, Anika Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.1 million in 2021, then tumbled by 51.84% to $510000.0 in 2022, then crashed by 33.73% to $338000.0 in 2023, then soared by 126.33% to $765000.0 in 2024, then fell by 1.96% to $750000.0 in 2025.
  • Its Other Accumulated Expenses was $750000.0 in Q3 2025, compared to $641000.0 in Q2 2025 and $776000.0 in Q1 2025.